Partial Substitution of Thyroxine (T4) with Tri-Iodothyronine in Patients on T4Replacement Therapy: Results of a Large Community-Based Randomized Controlled Trial
The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Conflicting results have recently been published about the benefits of combined T(4) and T(3) in treating hypothyroid patients. However, these studies may have been underpowered to detect differences in psychological well-being specifically related to T(4) replacement. We conducted a large, double-blind, randomized controlled trial of partial substitution of 50 microg T(4) by 10 microg T(3) vs. the original dose of T(4) in 697 hypothyroid patients. Thyroid function showed a rise in TSH (132%), a fall in free T(4) (35%, P < 0.001), and unchanged basal free T(3) levels (P = 0.92). At 3 months, there was a large (39%) placebo effect improvement in psychiatric caseness defined by the General Health Questionnaire (GHQ) 12 score in the control group compared with baseline, and this was sustained at 12 months. Differences vs. the intervention (T(3)) group were more modest with improvements in GHQ caseness (odds ratio, 0.61; 95% confidence interval, 0.42, 0.90; P = 0.01) and Hospital Anxiety and Depression questionnaire-anxiety scores at 3 months (P < 0.03) but not GHQ Likert scores, Hospital Anxiety and Depression questionnaire-depression, thyroid symptoms, or visual analog scales of mood and the initial differences were lost at 12 months. These results may be consistent with a subgroup of patients showing transient improvement after partial substitution with T(3) but do not provide conclusive evidence of specific benefit from partial substitution of T(4) by T(3) in patients on T(4)…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“superiority on a minority of measures at certain time points was seen in two trials contributing 633 participants (47,48)”
From Evidence-Based Use of Levothyroxine/Liothyronine Combinations in Treating Hypothyroidism: A Consensus Document (2021) · cites this paper as [47]
In the citing paper
“whereas patients from another trial of 697 patients (611 with follow-up data; 573 still on study medication) had no treatment preference (47).”
From Evidence-Based Use of Levothyroxine/Liothyronine Combinations in Treating Hypothyroidism: A Consensus Document (2021) · cites this paper as [47]
In the citing paper
“Of the 14 combination therapy trials that have been completed, 10 employed once-daily LT3 administration (23,46,47,49,51,52,59,71,78,79), 4 employed twice-daily LT3 therapy (17,48,53,60), and none used three times a day LT3 therapy.”
From Evidence-Based Use of Levothyroxine/Liothyronine Combinations in Treating Hypothyroidism: A Consensus Document (2021) · cites this paper as [47]
In the citing paper
“Three trials of synthetic combination therapy (17,47,52) and one of DTE (58) have used thyroid-specific PROs.”
From Evidence-Based Use of Levothyroxine/Liothyronine Combinations in Treating Hypothyroidism: A Consensus Document (2021) · cites this paper as [47]
In the citing paper
“This was not achieved in five trials, with two trials having a lower TSH in the combination therapy group (including the Appelhof trial in 5:1 ratio group) (53,71), and three trials having a higher serum TSH in the combination therapy group (47,52,58).”
From Evidence-Based Use of Levothyroxine/Liothyronine Combinations in Treating Hypothyroidism: A Consensus Document (2021) · cites this paper as [47]
20 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
The validity of the Hospital Anxiety and Depression Scale
Bjelland, I., Dahl, A. A., Haug, T. T., & Neckelmann, D. (2002) · Journal of Psychosomatic Research · doi:10.1016/s0022-3999(01)00296-3 · Cited by 9,779 · cited 10×
“However, no difference was seen in the TSQ scores, sleep, neuromuscular symptoms, HADS depression category, or visual analog scales, and the percentage of patients reporting that they felt better on direct questioning was not different (well-being question, Table 2).”
MethodInfluentialHollowell, J. G., Staehling, N. W., Flanders, W. D., Hannon, W. H., Gunter, E. W., Spencer, C. A., & Braverman, L. E. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.87.2.489 · Cited by 4,279 · cited 6×
“808 J Clin Endocrinol Metab, February 2005, 90(2):805–812 Saravanan et al.”
BackgroundInfluentialThe Validity of Two Versions of the GHQ in the WHO Study of Mental Illness in General Health Care
GOLDBERG, D. P., GATER, R., SARTORIUS, N., USTUN, T. B., PICCINELLI, M., GUREJE, O., & RUTTER, C. (1997) · Psychological Medicine · doi:10.1017/s0033291796004242 · Cited by 3,657 · cited 5×
“The GHQ-12 and the TSQ were scored both by the Likert method (0–3 per question, maximum score 36-most dissatisfied, linear method) and by the GHQ method (0, 0, 1, 1, maximum score 12-most dissatisfied) to assess caseness (using a threshold score of 3 or more, categorical method) (23, 24).”
MethodInfluentialThe Colorado Thyroid Disease Prevalence Study
Canaris, G. J., Manowitz, N. R., Mayor, G., & Ridgway, E. C. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.4.526 · Cited by 2,824
The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham Survey
Vanderpump, M. P. J., Tunbrldge, W. M. G., French, J. M., Appleton, D., Bates, D., Clark, F., Evans, J. G., Hasan, D. M., Rodgers, H., Tunbridge, F., et al. (1995) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1995.tb01894.x · Cited by 2,432
Bianco, A. C., Salvatore, D., Gereben, B., Berry, M. J., & Larsen, P. R. (2002) · Endocrine Reviews · doi:10.1210/edrv.23.1.0455 · Cited by 1,853
Saravanan, P., Chau, W. ‐., Roberts, N., Vedhara, K., Greenwood, R., & Dayan, C. M. (2002) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2002.01654.x · Cited by 514 · cited 12×
“The GHQ-12 and the TSQ were scored both by the Likert method (0–3 per question, maximum score 36-most dissatisfied, linear method) and by the GHQ method (0, 0, 1, 1, maximum score 12-most dissatisfied) to assess caseness (using a threshold score of 3 or more, categorical method) (23, 24).”
BackgroundMethodInfluentialSelf-citationBunevičius, R., Kažanavičius, G., Žalinkevičius, R., & Prange, A. J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199902113400603 · Cited by 482 · cited 1×
“5 g T3 significantly improves mood although not cognitive function (17), but more recently, five other trials have shown either no benefit (18–21) or a worse outcome (22).”
BackgroundValidation of the General Health Questionnaire in a young community sample
Banks, M. H. (1983) · Psychological Medicine · doi:10.1017/s0033291700050972 · Cited by 383
Zulewski, H., Müller, B., Exer, P., Miserez, A. R., & Staub, J.-J. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.3.3810 · Cited by 338
Cited by
Items 101–135 of 135
Pinchera, A., & Santini, F. (2005) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0027 · Cited by 5
Potential uses of T3 in the treatment of human disease
Danzi, S. E., & Klein, I. L. (2005) · Clinical cornerstone · doi:10.1016/s1098-3597(05)80052-3 · Cited by 6
Psychosocial Factors in Patients with Thyroid Disease
Mandincov, P. (2012) · InTech eBooks · doi:10.5772/36477 · Cited by 3
Low Triiodothyronine Syndrome and Depression in Patients with Chronic Heart Failure
Bunevičius, R. (2009) · Springer eBooks · doi:10.1007/978-88-470-1143-4_18 · Cited by 5
Eligar, V. S., Taylor, P. N., Okosieme, O. E., & Dayan, C. M. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803592-4.00077-8 · Cited by 3
Self-citationLiothyronine use in primary hypothyroidism — current concepts
Concepción‐Zavaleta, M. J., Ildefonso-Najarro, S. P., Paz‐Ibarra, J., Fernández-Dávila, F. V., Condori, D. C. D.-G., Rivera-Fabián, K., Herrera-Cabezas, R. G., & Urteaga, L. A. C. (2021) · Endokrynologia Polska · doi:10.5603/ep.a2021.0093 · Cited by 4
“nature of the trial should be agreed with the patient before commencing, and there should be agreement that LT4 monotherapy will once again be the mainstay treatment if no significant benefit is seen [46].”
Jonklaas, J. (2025) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2025.2492789 · Cited by 2
“The previously described secondary analysis of the Saravanan study [52] by Panicker et al [36] was likely underpowered, as was the recent study by Brigante et al [59], which studied both deiodinase and monocarboxylate transporter-10 polymorphisms.”
Валерьевич, П. А., & Fadeyev, V. V. (2010) · Clinical and experimental thyroidology · doi:10.14341/ket20106458-68 · Cited by 4
Лечение первичного гипотиреоза: нерешенные вопросы
Моргунова, Т. Б., Madiyarova, M. S., & Fadeyev, V. V. (2015) · Clinical and experimental thyroidology · doi:10.14341/ket2015122-34 · Cited by 4
“[13] уча ст во ва ло 697 па ци ен тов с ги по ти ре о зом.”
McDermott, M., & Ridgway, E. C. (2009) · CRC Press eBooks · doi:10.3109/9781420070651-5 · Cited by 4
Hadi, Z. M., Alidrisi, H. A., & Mansour, A. A. (2024) · Cureus · doi:10.7759/cureus.58370 · Cited by 4
“However, numerous clinical studies comparing T4 alone to T3+T4 regimens in hypothyroidism have not consistently demonstrated the superiority of combination therapy [25,26].”
BackgroundIs euthyroidism within reach for all?
Jonklaas, J. (2023) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2023.2267120 · Cited by 2
Options of Replacement Therapy in Hypothyroidism
Valentine, V., Galina, A., & Morgunov, T. (2012) · InTech eBooks · doi:10.5772/31226 · Cited by 1
Combined LT3 and LT4 therapy for precision medicine: easier with TTCombo system
Gatta, E., Ippolito, S., & Cappelli, C. (2024) · Endocrine · doi:10.1007/s12020-024-04084-9 · Cited by 1
Clinical thyroidology: beyond the 1970s’ TSH-T4 Paradigm
Lindner, H. H. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1529791 · Cited by 2
Social and Medical Aspects of Replacement Thyroxine Therapy: Factors of Compensation Quality
Моргунова, Т. Б., Manuilova, Y., & Fadeyev, V. V. (2007) · Clinical and experimental thyroidology · doi:10.14341/ket20073312-24 · Cited by 3
“Эта ан# кета не была валидизирована до проведения популя# ционного исследования, однако в дальнейшем она использовалась дважды в исследованиях по сравне# нию монотерапии L#T4 и комбинированной терапии L#T4 и трийодтиреонином [57, 70].”
Importance of Thyroid Hormone Replacement Therapy in Patients with Medullary Thyroid Cancer
Jonklaas, J. (2016) · Springer eBooks · doi:10.1007/978-3-319-39412-1_13 · Cited by 2
Book Review: Ultra-Metabolism: The Simple Plan for Automatic Weight Loss
Bessesen, D. H. (2006) · Obesity Management · doi:10.1089/obe.2006.2.245 · Cited by 2
Duntas, L. H. (2005) · PubMed · Cited by 1
T4 versus T3 and T4: Is It a Real Controversy?
Weetman, A. P. (2007) · Hormone Research in Paediatrics · doi:10.1159/000097569
Thyroid Replacement Therapy: The Hidden Challenges
Rahim, A., & Goundrey-Smith, S. (2014) · Journal of Endocrinology and Metabolism · doi:10.4021/jem.v3i6.200
“It has however, been suggested that studies of levothyroxine and liothyronine combinations were not adequately powered to detect and evaluate changes in psychological well-being [37], and that the review may have compared studies with different patient groups and outcomes [13].”
ResultAl-Juburi, S. A., Taresh, H. R., Mahmood, A. A., & Al-Fatlawi, R. B. (2015) · European Scientific Journal ESJ
L-T4 and L-T3 combined treatment vs L-T4 alone
Wiersinga, W. M. (2007) · Annales d Endocrinologie · doi:10.1016/j.ando.2007.06.008 · Cited by 2
Treatment of Hypothyroidism: Utility of Adding T3 (Liothyronine)
Tsai, J. N., & Stathatos, N. (2015) · Springer eBooks · doi:10.1007/978-1-4939-2059-4_11
Baron, H. L., & SINGER, P. A. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-3291-5.50042-1 · Cited by 2
Optimal Management of Hypothyroidism: Incremental Improvements for use in 2016 and Beyond
Hennessey, J. V. (2016) · Endocrine Practice · doi:10.4158/ep161586.co
Kant, R., & Verma, V. K. (2018) · Endocrinology & Metabolic Syndrome · doi:10.4172/2161-1017.1000e127
“In some of these studies patients preferred combination LT4/LT3 even though no or minimal statistically significant differences were observed in primary outcomes [6-19].”
BackgroundModalities of Thyroid Hormone Administration and Correlates Between Blood and Tissue Levels
Celi, F. S. (2020) · Springer eBooks · doi:10.1007/978-3-030-36871-5_26
Sfeir, J. G., & Gharib, H. (2022) · Springer eBooks · doi:10.1007/978-3-030-90684-9_2 · Cited by 1
Perros, P. (2024) · Copernicus books · doi:10.1007/978-3-031-58287-5_6
Perros, P. (2024) · Copernicus books · doi:10.1007/978-3-031-58287-5_5
Metadata
- Authors
- Saravanan, P., Simmons, D. J., Greenwood, R., Peters, T. J., & Dayan, C. M.
- Affiliations
- University of Bristol (GB)
- Bristol Royal Infirmary (GB)
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2005-02
- Volume
- 90
- Issue
- 2
- Pages
- 805-812
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2054867435
- Cited by
- 136
- References
- 25
- Citations by year
- 2025: 6 · 2024: 6 · 2023: 3 · 2022: 8 · 2021: 7 · 2020: 7 · 2019: 8 · 2018: 14 · 2017: 3 · 2016: 11 · 2015: 5 · 2014: 5 · 2013: 3 · 2012: 7
- FWCI
- 4.91
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Explore Bristol Research (publishedVersion)
- ORCA Online Research @Cardiff (Cardiff University) (submittedVersion)
- Bristol Research (University of Bristol) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
- Health Sciences › Medicine › Surgery › Thyroid and Parathyroid Surgery
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Keywords
- hypothyroidism, thyroxine replacement, triiodothyronine, placebo effect, psychiatric symptoms, anxiety, depression, thyroid function, thyroid-stimulating hormone, free thyroxine
- MeSH terms
- Adolescent, Adult, Aged, Double-Blind Method, Follow-Up Studies, Humans, Hypothyroidism, Middle Aged, Thyrotropin, Thyroxine, Time Factors, Triiodothyronine, Reproducibility of Results, Treatment Outcome, Hormone Replacement Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.